C4 Therapeutics Reports Q4 and Full Year 2022 Financial Results with Net Loss of $128.2M and Cash Runway to End of 2024

C4 Therapeutics, Inc.

2022-FY EPS reported -$2.62 revenue$31,096,000

Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.
Net loss for 2022 was $128.2M ($2.62 per share) compared to $83.9M ($1.82 per share) in 2021, driven by increased R&D and G&A expenses.
Cash, cash equivalents and marketable securities totaled $337.1M as of Dec 31, 2022, expected to fund operations through end of 2024.
Phase 1 dose escalation data for CFT7455 (multiple myeloma) and CFT8634 (synovial sarcoma) expected in second half of 2023.
IND submission for CFT8919 (EGFR L858R degrader) on track for first half of 2023; CFT1946 Phase 1/2 trial dosing first patient in January 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.